***********************************
Brakke Consulting’s
Animal Health News & Notes for July 20, 2018
Copyright © Brakke Consulting, Inc.
Editor: Lynn Fondon DVM MBA
************************************
IN THE NEWS:
Brakke Consulting news
Multi-client studies
earnings news
Neogen
Orion Animal Health
Virbac
other news
Agolin
Alivira Animal Health
Apiam Animal Health
Aviagen
Biogal Galed Labs
Boehringer Ingelheim
Diamondback Drugs
IMI Global
International Genetic Solutions
Jurox
Merial
Novus International
Petco
Plumbline Life Sciences
R2P Pet
Ultra Paws
Valley Agricultural Software
Vault Dairy Technologies
Wedgewood Pharmacy
***********************************
CLARIFICATION
Last week’s newsletter included an item announcing Kindred Biosciences’ new product, Mirataz (mirtazapine transdermal ointment). The news item stated that the product is for the “management of weight loss in cats.” Mirataz is designed to manage unintended weight loss in cats caused by varying underlying conditions, such as chronic kidney disease, diabetes or cancer. It is not intended to enhance weight loss in cats that are overweight or obese. Unintended weight loss in cats is a serious and potentially fatal condition that represents the leading cause of visits to the veterinarian for cats.
***********************************
BRAKKE CONSULTING, INC.
MULTI-CLIENT STUDIES
Brakke Consulting is an industry leader in timely market research on topics of high interest to stakeholders in the animal health, pet and veterinary markets. Reports published in the past year include:
Veterinary Home Delivery Report (May 2018)
Pain Management Products for Dogs and Cats (April 2018)
Veterinary Technical Services Study (March 2018)
Equine Mega Study IV (January 2018)
Manufacturer Sales Force Effectiveness Study (biannual report coming December 2018)
Distributor Effectiveness Study (December 2017)
US Flea Control and Heartworm Markets (December 2017)
Cancer in Dogs and Cats (2017)
New Strategies for Health & Performance in US Livestock & Poultry Production (2017)
Prices for reports vary. For more information about these or other reports, visit our website at https://brakkeconsulting.com/our-services/information/multi-client-studies/ or contact us at info@BrakkeConsulting.com
***********************************
COMPANY EARNINGS RELEASES
• Virbac reported results for the second quarter of 2018. Net revenue was EUR 236 million ($275 million), a decline of 1% compared to the second quarter of 2017. Revenue grew 4% for the quarter at constant exchange rates. (company website)
• Neogen Corporation announced results for its 2018 fiscal year, which ended May 31. Revenues for the entire fiscal 2018 increased 11% to $402 million. Net income for the full 2018 fiscal year increased 44% to $63.1 million. Animal Safety revenues for the year were $206 million, an increase of 8% compared to the prior year. (company press release)
• Orion Animal Health reported results for the second quarter of 2018. Animal Health sales were EUR 18.7 million ($21.7 million), a decline of 14.5% compared to the prior-year quarter. (Animal Pharm)
**********************************
COMPANY NEWS RELEASES
• Boehringer Ingelheim announced the launch of Centragard (eprinomectin and praziquantel transdermal solution), a monthly topical heartworm preventive for cats that also treats and controls hookworms, roundworms, and tapeworms. The company will begin taking orders for Centragard in August. (Todays Veterinary Business)
• The FDA has approved Merial’s NexGard (afoxolaner) for the prevention of Borrelia burgdorferi (B. burgdorferi) infections by killing Black-legged ticks (Ixodes scapularis), which carry the bacterium. The data presented by Merial in the supplemental application measured the transmission of B. burgdorferi, which causes Lyme disease, to dogs after exposure to infected ticks, and demonstrated that transmission was prevented as a direct result of killing the ticks. The study did not measure whether the product affected rates of illness from Lyme disease in dogs. (FDA)
• Jurox Animal Health announced that the FDA’s Center for Veterinary Medicine has authorized Alfaxan Multidose, whose preserved formulation permits its use up to 28 days after the vial is opened. The products is approved for use in dogs and cats. (Todays Veterinary Business)
• Wedgewood Pharmacy and Diamondback Drugs announced that the two pharmacies are merging. The new, combined company will operate as Wedgewood Pharmacy. Financial terms were not disclosed. (Business Wire)
• Petco has launched PetCoach, a new kind of pet store that offers a suite of services at deep discounts for a monthly fee. Shoppers can pay $9 a month to access the PetCoach services – including grooming, training, veterinary care, nutrition consultations, day care, mobile vet house calls, and dog walking – at a discounted price. The PetCoach concept has no registers or dedicated cashiers; instead, it features roaming “pet coaches” who assist shoppers by scheduling appointments or checking them out using iPad minis. The first PetCoach location opened in San Marcos, California, last week. (Business Insider)
• R2P Pet, a manufacturer of pet toys, beds, and accessories, announced it has acquired Ultra Paws. Ultra Paws designs and develops a full range of dog gear, including boots, apparel and accessories. Financial terms were not disclosed. (Pet Product News)
• IMI Global announced it has established an exclusive partnership with International Genetic Solutions (IGS) to offer the IGS Feeder Profit Calculator within its suite of verification services for beef producers. (Feedstuffs)
• Valley Agricultural Software (VAS) and Vault Dairy Technologies announced a collaboration that will see data from the VAS Platform integrated into Vault’s dairy management systems to enhance functionality and reporting for users. (Animal Pharm)
• EU Novus International announced it has received EU approval for its Avimatrix poultry feed additive to improve the performance of chickens for fattening and laying. (Animal Pharm)
• EU Alivira Animal Health announced it has received a CEP (Certificate for European Pharmacopeia) for Xylazine API. (company announcement)
• ISRAEL Biogal Galed Labs announced the commercialization of a new PCRun Veterinary Molecular Detection Kit: the PCRun Canine Distemper RNA Molecular Detection Test Kit. This kit compliments well the preexisting PCRun Parvovirus Molecular Detection Kit. The kit is available in the Far East, South America, and Europe. (company announcement)
• AUSTRALIA Apiam Animal Health and Korean company Plumbline Life Sciences have entered into an agreement that gives Apiam exclusive distribution rights for some of Plumbline’s patented immunotherapy technology products for the pig, cattle and horse industries in Australia and New Zealand. Apiam will also be given the first option to market future therapies for companion animals when those become available in Australia, as well as current and future pig products in the US and Canada.(BendigoAdvertiser.com.au)
• BRAZIL Aviagen announced it has invested $27 million over the past two years to increase its grandparent and parent stock production capacity on farms and hatcheries in Brazil. The expanded capacity was needed to meet a growing demand for both breeders and broilers in Latin America. (Feedstuffs)
• EU Agolin announced it has earned a Certificate of Achievement from The Carbon Trust Assurance for its Agolin Ruminant feed additive for cattle. Agolin Ruminant is a first-of-its-kind plant-based feed additive that reduces methane emissions in cows and improves feed efficiency. (Animal Pharm)
***********************************
ANIMAL HEALTH NEWS
• US – MEAT REGULATION The US meat industry and consumer groups are raising red flags over the potential for the FDA to regulate lab-grown meat, poultry and seafood products. The concerned parties suggest the FDA and USDA should work together with all stakeholders before any decisions are made about which agency gets oversight of emerging products. (Animal Pharm)
• US – REBRANDING The Kansas City Area Life Sciences Institute (KCALSI) announced it is rebranding as BioNexus KC to highlight the organization’s work in both animal and human health. (Animal Pharm)
************************************
AVMA ANNUAL CONVENTION
July 13-17, 2018
DENVER
The American Veterinary Medical Association held its annual convention in Denver July 13 – 17. The convention hosted over 9,000 attendees, including nearly 5,000 veterinarians, and hosted some 330 exhibitors in the Exhibit Hall. The convention offered a variety of learning opportunities, including over 800 continuing education sessions and a number of informational events in the Exhibit Hall. A key focus of the 2018 Convention was exploring tools and resources available to help veterinarians, technicians and students address wellbeing issues impacting the profession.
************************************
BRAKKE CONSULTING VIEWPOINT
The AVMA‘s Annual Convention in Denver this past week was well attended and offered a wide variety of interesting educational opportunities and events. Veterinarian and veterinary staff wellbeing was a hot topic at the conference, including everything from CE lectures, to the AVMA’s Center for Wellbeing, to a wall in the Exhibit Hall where attendees could post tips on maintaining your mental wellbeing, to goat yoga (a sold out event!). Read more about veterinary wellbeing in the Merck Veterinary Wellbeing study on our website at https://brakkeconsulting.com/our-services/information/market-research/merck-veterinary-wellbeing-study/.
Another hot topic was the burgeoning telehealth movement. The AVMA recently added a telehealth resource area on its website, and the Exhibit Hall featured “Vet Clinic Live!” and “The Connected Veterinary Experience” exhibits, as well as a Tech Hub where companies offering these services had booths to educate attendees. Whether our profession likes it or not, telehealth is coming to veterinary medicine and it behooves us to stay ahead of the movement. Stay tuned: Brakke Consulting will be publishing a report on the telehealth landscape soon!
Lynn Fondon
Editor
**********************************
This electronic newsletter is the sole property of Brakke Consulting, Inc.
Any use of the contents herein should be approved by and appropriately attributed to Brakke Consulting, Inc.
For more information about Brakke Consulting’s services and syndicated studies, visit our website at www.brakkeconsulting.com.
Brakke Consulting, Inc.
12005 Ford Rd., Suite 530
Dallas, TX 75234 USA
English (United States) 
Portuguese